Dan H Barouch

US Patent:

20070298051, Dec 27, 2007

Filed:

Nov 19, 2004

Appl. No.:

10/580105

Inventors:

Dan Barouch - Boston MA, US
Shawn Sumida - Honolulu HI, US
Norman Letvin - Newton MA, US

Assignee:

BETH ISRAEL DEACONESS MEDICAL CENTER - Boston MA

International Classification:

A61K 48/00
A61K 31/7088
A61K 38/02
A61P 31/00
A61P 33/00
A61P 37/06
A61P 37/08
A61P 35/00
A61P 31/18
A61K 38/45
A61K 39/12

US Classification:

424199100, 424093200, 424094500, 514012000, 514044000

Abstract:

The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which includes an immunogen and Flt3L in combination with MIP-1α or MIP-3α. The methods of the present invention can be used for the prevention and treatment of various pathological states, including for example, cancer, microbial infections, autoimmune diseases, tissue rejection, and allergic reactions.

US Patent:

20080199939, Aug 21, 2008

Filed:

Oct 12, 2005

Appl. No.:

11/665276

Inventors:

Menzo Jans Emco Havenga - Alphen aan den Rijn, NL
Dan H. Barouch - Brookline MA, US

Assignee:

CRUCELL HOLLAND B.V. - Leiden
BETH ISRAEL DEACONESS MEDICAL CENTER INC. - Brookline MA

International Classification:

C12N 7/00

US Classification:

4352351

Abstract:

The present invention relates to recombinant adenoviral vectors based on adenoviruses that encounter pre-existing immunity in a minority of the human population and which harbour a chimeric capsid. The chimeric capsid comprises fiber proteins that have at least the knob domain of a human adenovirus that binds to the Coxsackievirus and Adenovirus Receptor (CAR) and a hexon protein from an adenovirus serotype that encounters pre-existing immunity in a low percentage of the human population.

US Patent:

20100143302, Jun 10, 2010

Filed:

Mar 15, 2007

Appl. No.:

12/225259

Inventors:

Menzo Jans Emko Havenga - Alphen aan den Rijn, NL
Dan H. Barouch - Brookline MA, US

International Classification:

A61K 45/00
C07H 21/00
C12N 7/01
C12N 15/74
A61P 37/04

US Classification:

424 932, 536 231, 536 235, 536 2372, 536 237, 4352351, 4353201

Abstract:

The present application relates to recombinant adenoviruses, more in particular those that encounter low levels of pre-existing neutralizing activity in hosts that are in need of treatment or vaccination. Particularly, the invention relates to recombinant vectors derived from two subgroup D adenoviruses: Ad26 and Ad48.

US Patent:

20120045472, Feb 23, 2012

Filed:

Apr 8, 2011

Appl. No.:

13/082601

Inventors:

Stephen C. Harrison - Brighton MA, US
Bing Chen - West Wood MA, US
Dan C. Barouch - Brookline MA, US
Joseph P. Nkolola - Watertown MA, US
Michael Scott Seaman - West Roxbury MA, US

Assignee:

Beth Israel Deaconess Medical Center - Boston MA
Children's Medical Center Corporation - Boston MA

International Classification:

A61K 39/21
A61P 37/04
A61P 31/18
C12N 15/63
C07K 14/16

US Classification:

4242081, 4353201, 530350

Abstract:

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

US Patent:

20120076812, Mar 29, 2012

Filed:

Nov 18, 2009

Appl. No.:

13/130018

Inventors:

Dan H. Barouch - Brookline MA, US
Bette T. Korber - Los Alamos NM, US
William M. Fischer - Los Alamos NM, US

International Classification:

A61K 39/21
C12P 21/02
C12N 15/63
C12N 15/48
A61P 31/18

US Classification:

4241881, 536 2372, 4353201, 435 693

Abstract:

The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

US Patent:

20210388032, Dec 16, 2021

Filed:

Jul 28, 2021

Appl. No.:

17/387105

Inventors:

- Titusville NJ, US
- Boston MA, US
Mark Johannes Gerardus BAKKERS - Haarsteeg, NL
Rinke BOS - Oegstgeest, NL
Frank WEGMANN - Leiden, NL
David Adrianus Thedorus Maria ZUIJDGEEST - Den Haag, NL
Dan H. BAROUCH - Newton MA, US
An VANDEBOSCH - Herentals, BE
Mathieu Claude Michel le GARS - Antwerp, BE
Jerald C. SADOFF - Washington DC, US

International Classification:

C07K 14/005
A61P 31/14
C12N 7/00
C12N 15/86
A61K 39/215

Abstract:

The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

US Patent:

20210246170, Aug 12, 2021

Filed:

Jan 30, 2021

Appl. No.:

17/163357

Inventors:

- Titusville NJ, US
- Boston MA, US
Mark Johannes Gerardus BAKKERS - Haarsteeg, NL
Rinke BOS - Oegstgeest, NL
Frank WEGMANN - Leiden, NL
David Adrianus Theodorus Maria ZUIJDGEEST - Den Haag, NL
Dan H. BAROUCH - Newton MA, US
An VANDEBOSCH - Herentals, BE
Mathieu Claude Michel le GARS - Antwerp, BE
Jerald C. SADOFF - Washington, D.C., US

International Classification:

C07K 14/005
A61P 31/14
C12N 7/00
C12N 15/86
A61K 39/215

Abstract:

The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

US Patent:

20210238262, Aug 5, 2021

Filed:

Apr 24, 2019

Appl. No.:

17/049800

Inventors:

- Bethesda MD, US
- Boston MA, US
- Silver Spring MD, US
Kayvon Modjarrad - Bethesda MD, US
Dan Barouch - Boston MA, US
Nelson L. Michael - Silver Spring MD, US
Gordon Joyce - Silver Spring MD, US

Assignee:

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Bethesda MD
The Beth Israel Deaconess Medical Center, Inc. - Boston MA
The Government of the United States as Represented by the Secretary of the Army - Silver Spring MD

International Classification:

C07K 16/10
A61P 31/14
G01N 33/569
G01N 33/563
A61K 39/12
C12N 7/00

Abstract:

The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.

Author:

Dan Barouch

ISBN #:

0763703087

Author:

Dan Barouch

ISBN #:

0763703117